Table 2.
Comparison of the clinical characteristics between symptomatic and asymptomatic patients.
| Variables | Symptomatic group (n = 372) | Asymptomatic group (n = 205) | P value |
|---|---|---|---|
| Age, mean (SD) (years) | 67.5 (9.9) | 70.7 (8.5) | < 0.001 |
| Sex, men, n (%) | 185 (49.7) | 118 (57.6) | 0.07 |
| BMI, median (IQR) (kg/m2) | 22.2 (19.6–24.2) | 22.1 (20.1–25.1) | 0.15 |
| Weight loss, yes, n (%)a | 159 (59.3) | 57 (32.0) | < 0.001 |
| Tumor size, median (IQR) (mm) | 35 (27–45) | 25 (19–32) | < 0.001 |
| Tumor location, n (%) | |||
| Head | 203 (54.6) | 77 (37.6) | < 0.001 |
| Body | 99 (26.6) | 91 (44.4) | |
| Tail | 69 (18.5) | 36 (17.6) | |
| Multiple | 1 (0.3) | 1 (0.5) | |
| Clinical stage, n (%) | |||
| 0 | 2 (0.5) | 6 (2.9) | < 0.001 |
| I | 33 (8.9) | 79 (38.5) | |
| (IA) | 8 (2.2) | 39 (19.0) | |
| (IB) | 25 (6.7) | 40 (19.5) | |
| II | 44 (11.8) | 38 (18.5) | |
| III | 100 (26.9) | 35 (17.1) | |
| IV | 193 (51.9) | 47 (22.9) | |
| Treatment, n (%) | |||
| Surgery | 96 (25.8) | 132 (64.4) | < 0.001 |
| Surgery only | 4 (1.1) | 17 (8.3) | |
| Surgery with neoadjuvant treatment | 5 (1.3) | 4 (2.0) | |
| Surgery with adjuvant treatment | 34 (9.1) | 50 (24.4) | |
| Surgery with neoadjuvant and adjuvant treatments | 53 (14.2) | 61 (29.8) | |
| Chemotherapy or chemoradiotherapy | 219 (58.9) | 60 (29.3) | |
| Best supportive care | 54 (14.5) | 12 (5.9) | |
| Others | 3 (0.8) | 1 (0.5) | |
| Risk factors, n (%) | |||
| DM | 172 (46.2) | 122 (59.5) | 0.002 |
| Obesity (> BMI 30 kg/m2) | 12 (3.2) | 9 (4.4) | 0.47 |
| Tobacco use | 187 (50.3) | 105 (51.2) | 0.83 |
| Heavy alcohol consumption (> 40 g ethanol/day)b | 47 (13.1) | 22 (10.9) | 0.47 |
| Family history of pancreatic cancerc | 47 (14.2) | 21 (10.9) | 0.28 |
| IPMN/Pancreatic cyst | 30 (8.1) | 55 (26.8) | < 0.001 |
| Chronic pancreatitis | 3 (0.8) | 6 (2.9) | 0.075 |
SD standard deviation, BMI body mass index, IQR interquartile range, DM diabetes mellitus, IPMN intraductal papillary mucinous neoplasm.
aData from 268 symptomatic and 178 asymptomatic patients.
bData from 360 symptomatic and 201 asymptomatic patients.
cData from 330 symptomatic and in 192 asymptomatic patients.